These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 33296678)

  • 1. Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease.
    Sharpton SR; Schnabl B; Knight R; Loomba R
    Cell Metab; 2021 Jan; 33(1):21-32. PubMed ID: 33296678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy.
    Fianchi F; Liguori A; Gasbarrini A; Grieco A; Miele L
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.
    Kuraji R; Shiba T; Dong TS; Numabe Y; Kapila YL
    World J Gastroenterol; 2023 Feb; 29(6):967-996. PubMed ID: 36844143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.
    Bluemel S; Williams B; Knight R; Schnabl B
    Am J Physiol Gastrointest Liver Physiol; 2016 Dec; 311(6):G1018-G1036. PubMed ID: 27686615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.
    Jayakumar S; Loomba R
    Aliment Pharmacol Ther; 2019 Jul; 50(2):144-158. PubMed ID: 31149745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the microbiome in NAFLD and NASH.
    Kolodziejczyk AA; Zheng D; Shibolet O; Elinav E
    EMBO Mol Med; 2019 Feb; 11(2):. PubMed ID: 30591521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery.
    Martínez-Montoro JI; Kuchay MS; Balaguer-Román A; Martínez-Sánchez MA; Frutos MD; Fernández-García JC; Ramos-Molina B
    Obes Rev; 2022 Feb; 23(2):e13367. PubMed ID: 34729904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function.
    Sharpton SR; Ajmera V; Loomba R
    Clin Gastroenterol Hepatol; 2019 Jan; 17(2):296-306. PubMed ID: 30196156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interaction between the gut microbiota and dietary carbohydrates in nonalcoholic fatty liver disease.
    Park G; Jung S; Wellen KE; Jang C
    Exp Mol Med; 2021 May; 53(5):809-822. PubMed ID: 34017059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease.
    Aqel B; DiBaise JK
    Nutr Clin Pract; 2015 Dec; 30(6):780-6. PubMed ID: 26449892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA; Marsano LS; McClain CJ
    Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diet and gut microbiome in fatty liver and its associated liver cancer.
    Pan Y; Zhang X
    J Gastroenterol Hepatol; 2022 Jan; 37(1):7-14. PubMed ID: 34664301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates.
    Khan A; Ding Z; Ishaq M; Bacha AS; Khan I; Hanif A; Li W; Guo X
    Int J Biol Sci; 2021; 17(3):818-833. PubMed ID: 33767591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
    Boursier J; Diehl AM
    Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications.
    Fang J; Yu CH; Li XJ; Yao JM; Fang ZY; Yoon SH; Yu WY
    Front Cell Infect Microbiol; 2022; 12():997018. PubMed ID: 36425787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetics and Epigenetics in the Clinic: Precision Medicine in the Management of Fatty Liver Disease.
    Cespiati A; Youngson NA; Tourna A; Valenti L
    Curr Pharm Des; 2020; 26(10):998-1009. PubMed ID: 31969087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.
    Song Q; Zhang X
    Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease.
    Park E; Jeong JJ; Won SM; Sharma SP; Gebru YA; Ganesan R; Gupta H; Suk KT; Kim DJ
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.